Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full ...

Milestones Include Top-Tier 3-Year Accreditations from OASAS and The Joint Commission, Staff Growth to Over 20 ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE- Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...

Following a successful launch in 2024, The Centers announced the expansion of its Walk-in Medication Assisted Treatment Clinic, or WinMAT, earlier this year, with a second site opening at its ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

The company raised its 2025 guidance, with Ciaffoni indicating, "We now expect total net revenue in 2025 to be up versus 2024, driven by SUBLOCADE growth of 10% at the midpoint." Preblick stated, "Our ...

Indivior is already profitable and cash-generative, and is set to grow significantly in 2026. Its key medication's delivery system offers opioid use disorder patients more reliable outcomes. According ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

RICHMOND - Indivior PLC (NASDAQ:INDV), a pharmaceutical company with a market capitalization of $3.1 billion and an impressive 207% return over the past year, announced Wednesday that a new clinical ...